• Sofie Rosalie Joris
  • Thierry Pieters
  • Anne Sibille
  • Frederique Bustin
  • Laurence Jacqmin
  • HR Kalantari
  • VEERLE SURMONT
  • Jean-Charles Goeminne
  • frederic Clinckart
  • Karin Pat
  • Wim Demey
  • Koen Deschepper
  • Marc Lambrechts
  • Stephane Holbrechts
  • Denis Schallier
  • Lore Decoster
Objectives To compare real life effectiveness and safety of nivolumab in patients with non-small cell lung cancer (NSCLC), according to age and Eastern Cooperative Group performance status (ECOG-PS). Methods We performed a retrospective analysis of patients treated with nivolumab for NSCLC within a Belgian compassionate use program from July 2015 until December 2016. Safety and effectiveness were compared between patients aged ≥70 years and < 70 years and between ECOG-PS 0/1 and ≥ 2. Results A total of 324 patients with NSCLC were included. There was no significant difference between older (≥70) and younger (<70 years) patients with regards to progression free survival (PFS) (4 months (95%CI 2.6;4.8) versus 3.7 months (95%CI 1;7), p = 0.483) and overall survival (OS) (9.3 months (95% CI 5.5;13.1 months) versus 8.4 months (95%CI 6.3; 10.5), p = 0,638). Patients with an ECOG-PS ≥2 had a significant lower median PFS and OS compared to patients with an ECOG-PS 0–1 (2.2 (95%CI 1.4; 2.9) versus 5.6 months (95%CI 4.1; 7.1), p = 0.001 and 3.4 (95%CI 2.3; 4.5) versus 11.1 months (95%CI 8.9; 13.2), p < 0.001 respectively). No significant difference in all grades or grade 3/4 adverse events (AEs) were observed between the different age groups (p = 0.526 and p = 0.603 respectively). Patients with an ECOG-PS 0/1 had significantly more all grades AEs (p = 0.009) but no difference in grade 3/4 AEs was observed (p = 0.406) compared to ECOG-PS ≥2. Conclusion This real life retrospective study confirms that safety and effectiveness of nivolumab is similar between different age groups, but that effectiveness is driven by performance status.
Original languageEnglish
Pages (from-to)796-801
Number of pages6
JournalJ Geriatr Oncol
Volume11
Issue number5
DOIs
Publication statusPublished - Jun 2020

    Research areas

  • Nivolumab, Non-small cell lung cancer, Older, Performance status

ID: 48975626